In addition to being a regular researcher at the CHU Research Center of Québec-Laval University (Regenerative Medicine Axis) and Assistant Professor in the Department of Ophthalmology and Otolaryngology-Head and Neck Surgery at the Faculty of Medicine of Laval University, Dr. Solange Landreville is a regular researcher at the Center for Research in Experimental Organogenesis at Laval University / LOEX. Her work focuses on the development of treatment for the metastatic stage of ocular melanoma, and the improvement of cell culture and tissue engineering models in ophthalmology.

Dr. Landreville is a Junior 1 Research Fellow with the Fonds de recherche du Québec – Santé (FRQS) and was the recipient of the Bernard-Belleau Award from the Association Francophone pour le savoir (ACFAS) in 2005.

Develop a treatment for metastatic uveal melanoma

Uveal melanoma is the most common primary intraocular tumor in adults, and the second most common type of melanoma after the skin. It is a sporadic cancer, and familial cases are very rare. It is therefore difficult to prevent or justify large-scale screening tests. Metastases to the liver occur in half of the cases, despite the success of the eye’s treatment. Translational research on uveal melanoma has progressed rapidly in the last decade, with the development of prognostic genetic tools, but the main obstacle to improving patient survival remains the notorious resistance of this cancer to treatment. We must therefore focus our efforts on the characterization of the tumor / metastatic microenvironment (hypoxia, stromal cells, extracellular matrix, epigenetic). This research is important because it will provide crucial information on the molecular mechanisms of resistance to cancer and stromal cell treatment. Any innovative treatment that will stop the growth of uveal melanoma cells in the liver could turn the deadly metastatic stage into a chronic disease, impacting the overall patient survival rate.

Study of oxygen’s effects on the physiology of different eye cell types

Cell culture is essential to better understand the physiology of normal and pathological cells, as well as tissue reconstruction. It is traditionally carried out in incubators with 21% oxygen (atmospheric rate), which does not represent physiological conditions. In fact, oxygen is transported by the blood and delivered to the tissues at rates lower than 14%. This physiological oxygen level varies from one tissue to another, as well as within the tissue depending on the vascularization and metabolic activity. There is also a significant decrease in oxygen supply (hypoxia) in tumors. Several ocular pathologies affecting Canadians involve oxygen deficiency in their progression, such as uveal melanoma (ocular cancer) and diabetic retinopathy (complication of diabetes). Transfer of results obtained through research to the clinic depends strongly on their physiological validity, and thus on the maintenance of biological functions in the cells in culture, which are close to those found in the tissues of origin. It is therefore essential to modulate oxygen levels for the improvement of cell culture and tissue engineering models in ophthalmology.

Hôpital Saint-Sacrement
1050, chemin Sainte-Foy
CUO-Recherche, Bureau H2-02
Québec, Québec
Canada G1S 4L8

Latest news

Data not available

20 entries « 1 of 4 »

Djigo AD, Berube J, Landreville S, Proulx S

Characterization of a tissue-engineered choroid.

Journal Article

Acta Biomater, 84 , pp. 305-316, 2019, ISSN: 1742-7061.

Abstract | Links:

Pepin F, Julien AS, Fugaru I, Lihimdi N, Thariat J, Landreville S, Mouriaux F

Regression rate of choroidal melanoma following iodine-125 brachytherapy is not associated with metastatic spread.

Journal Article

Melanoma Res, 2018, ISSN: 0960-8931.

Abstract | Links:

Weidmann C, Berube J, Piquet L, de la Fouchardiere A, Landreville S

Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines.

Journal Article

Clin Exp Metastasis, 35 (3), pp. 123-134, 2018, ISSN: 0262-0898.

Abstract | Links:

Bergeron E, Lihimdi N, Bergeron D, Landreville S

Orbital recurrence of iris melanoma 21 years after enucleation.

Journal Article

BMJ Case Rep, 2017 , 2017, ISSN: 1757-790X.

Abstract | Links:

Weidmann C, Pomerleau J, Trudel-Vandal L, Landreville S

Differential responses of choroidal melanocytes and uveal melanoma cells to low oxygen conditions.

Journal Article

Mol Vis, 23 , pp. 103-115, 2017.

Abstract | Links:

20 entries « 1 of 4 »

Active projects

  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2023-04-30
  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Rôle du microenvironnement tumoral et métastatique dans la progression du mélanome uvéal., Subvention, Fonds de recherche du Québec - Santé, Chercheur-boursier Juniors 1 et 2, Seniors, from 2015-07-01 to 2019-06-30

Recently finished projects

  • Analyse des mécanismes moléculaires régulés par l'oxygène dans les cellules de l'oeil, Partenariat, Fondation Canadienne pour l'innovation (La), Fonds des leaders John-R.-Evans (FLJR), from 2014-06-01 to 2017-09-30
  • Caractérisation des interactions synergiques entre les cellules cancéreuses du mélanome uvéal et les cellules stromales de leur environnement afin de mieux comprendre sa résistance thérapeutique., Subvention, Fonds de recherche du Québec - Santé, Réseaux thématiques de recherche, from 2016-04-01 to 2018-03-31
  • Human inducible pluripotent stem cells (IPSC) plateform, Subvention, La Fondation Neuro Canada / Brain Canada, Soutien aux plateformes technologiques (SSPT), from 2015-04-01 to 2018-03-31
  • Programme de recherche sur le mélanome uvéal., Subvention, Fondation du CHU de Québec, from 2017-05-05 to 2018-03-31
  • Recherche sur le mélanome oculaire (Fonds FMO DB-11), Subvention, Fondation des maladies de l'oeil (Formoeil Oculus Inc.), from 2017-02-01 to 2018-01-31
  • Régulation de l’hydroxyméthylation de l’ADN dans la progression du mélanome uvéal., Subvention, Fondation de l'Université Laval, from 2015-10-01 to 2018-03-31
  • Remodelage du microenvironnement hépatique et progression du mélanome uvéal: modèle murin de micro-métastases, Subvention, Fondation des maladies de l'oeil (Formoeil Oculus Inc.), from 2016-12-01 to 2018-12-30
  • Rôle du microenvironnement tumoral dans la progression du mélanome uvéal, Subvention, Fondation du CHU de Québec, from 2015-09-28 to 2016-09-27
  • Rôle du microenvironnement tumoral et métastatique dans la progression du mélanome uvéal., Subvention, Fonds de recherche du Québec - Santé, Établissement de jeunes chercheurs - Juniors 1, from 2015-07-01 to 2018-06-30
Data provided by the Université Laval research projects registery